ArticleBMC medical imaging2025
Knowledge discovery from database: MRI radiomic features to assess recurrence risk in high-grade meningiomas.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in the application of MRI radiomics in meningioma.Radiation oncology (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe used knowledge discovery from radiomics of T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted imaging (T1C) for assessing relapse risk in patients with high-grade meningiomas (HGMs).
methods279 features were extracted from each ROI including 9 histogram features, 220 Gy-level co-occurrence matrix features, 20 Gy-level run-length matrix features, 5 auto-regressive model features, 20 wavelets transform features and 5 absolute gradient statistics features. The datasets were randomly divided into two groups, the training set (~ 70%) and the test set (~ 30%). Combinations of data preprocessing methods, including normalization (Min-Max, Z-score, Mean), dimensionality reduction (Pearson Correlation Coefficients (PCC)), feature selector (max-Number, cluster) and ten-fold cross-validation were analyzed for their prediction performance. Kaplan-Meier curve, Cox proportional hazards regression model were used and concordance index (C-index), integrated Brier score (IBS) were selected. Model performance was assessed using the C-index.
resultsWHO grade, age, gender, histogram (Mean, Perc.90%, Perc.99%), Gray-level co-occurrence matrix (S(3, -3)DifVarnc, S(5, 5)Correlat, S(1, 0)SumEntrp, S(2, -2)InvDfMom), Teta1, WavEnLL_s-2 and GrVariance were identified as the significant recurrence factors. The pipeline using Mean_PCC_Cluster_10 of T1C yielded the highest efficiency with an IBS of 0.170, 0.188, 0.208 and C-index of 0.709, 0.705, 0.602 in the train, test and validation sets, respectively. The pipeline using MinMax_PCC_Cluster_19 of T2WI yielded the highest efficiency with an IBS of 0.189, 0.175, 0.185 and C-index of 0.783, 0.66, 0.649 in the train, test and validation sets. The pipeline using MinMax_PCC_Cluster_13 of T2WI + T1C yielded the highest efficiency with an IBS of 0.152, 0.164, 0.191 and C-index of 0.701, 0.656, 0.593 in the train, test and validation sets, respectively.
conclusionKnowledge discovery from MRI radiomic features can slightly help predict recurrence risk in HGMs. T2WI or T1C yielded better efficiency than T2WI + T1C. The parameters with the best power were Mean, Perc.99%, WavEnLL_s-2, Teta1 and GrVariance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.